COMPANY
Alpha Tau Medical
Alpha TAU Medical is a clinical-stage oncology company intratumoral alpha-emitting radiotherapeutics to address multiple solid tumor types, including those with few or no currently viable treatment options. From company website Source · Oct 12, 2026
Timeline
- Partnership Partnership / licensing: upfront not published; stated deal value $15M (kept separate from upfront), announced Jun 3, 2026. Source: SEC filing. source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer source ↗
- Trial start Not phased (device or behavioral study): Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT). source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer. source ↗
- Trial start Not phased (device or behavioral study): A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients. source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma source ↗
- Trial start Not phased (device or behavioral study): Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors source ↗
- Trial start —: A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT) source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia source ↗
- Trial start Not phased (device or behavioral study): Retreatment With Intratumoral Diffusing Alpha Radiation Emitters source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. source ↗
- Trial start Not phased (device or behavioral study): Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer source ↗
Upcoming milestones
- 2026-10 (ESTIMATED) · Not phased · Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer · NCT06698458
- 2026-10 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer · NCT04002479
- 2026-11 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) · NCT05657743
- Nov 1, 2026 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NCT06910306
- 2026-12 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients · NCT06615635
- 2026-12 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT) · NCT03737734
- 2026-12 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC · NCT05047094
- 2027-01 (ESTIMATED) · Not phased · Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer · NCT06755359
Funding
- Partnership / licensing: upfront not published; stated deal value $15M (kept separate from upfront), announced Jun 3, 2026. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 29
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06698458 | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | Not phased (device or behavioral study) | Recruiting | Jun 17, 2025 | 2026-10 (estimated) |
| NCT06910306 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma | Not phased (device or behavioral study) | Recruiting | Oct 1, 2025 | Nov 1, 2026 (estimated) |
| NCT06615635 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients | Not phased (device or behavioral study) | Recruiting | Jan 1, 2026 | 2026-12 (estimated) |
| NCT06755359 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer | Not phased (device or behavioral study) | Recruiting | Mar 1, 2026 | 2027-01 (estimated) |
| NCT04068155 | Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors | Not phased (device or behavioral study) | Recruiting | Apr 1, 2022 | 2027-01 (estimated) |
| NCT05781555 | Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors | Not phased (device or behavioral study) | Recruiting | Mar 22, 2023 | 2027-04 (estimated) |
| NCT05323253 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma | Not phased (device or behavioral study) | Active, not recruiting | Sep 21, 2022 | 2027-04 (estimated) |
| NCT05657743 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) | Not phased (device or behavioral study) | Recruiting | Aug 16, 2023 | 2026-11 (estimated) |
| NCT06026943 | Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer | Not phased (device or behavioral study) | Recruiting | May 6, 2026 | 2027-01 (estimated) |
| NCT04534127 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | Not phased (device or behavioral study) | Recruiting | Dec 22, 2020 | Jan 1, 2027 (estimated) |
| NCT05829291 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases | Not phased (device or behavioral study) | Recruiting | Oct 1, 2023 | 2027-02 (estimated) |
| NCT06202248 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer. | Not phased (device or behavioral study) | Recruiting | Mar 12, 2024 | 2027-06 (estimated) |
| NCT05632913 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer | Not phased (device or behavioral study) | Recruiting | Jul 1, 2023 | 2027-02 (estimated) |
| NCT07290998 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer | Not phased (device or behavioral study) | Not yet recruiting | 2026-05 | 2028-05 (estimated) |
| NCT03737734 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT) | Not phased (device or behavioral study) | Active, not recruiting | Dec 31, 2018 | 2026-12 (estimated) |
| NCT05047094 | Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC | Not phased (device or behavioral study) | Recruiting | Nov 2, 2021 | 2026-12 (estimated) |
| NCT03886181 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT) | Not phased (device or behavioral study) | Terminated | Jul 8, 2021 | Oct 13, 2024 (actual) |
| NCT04540588 | Retreatment With Intratumoral Diffusing Alpha Radiation Emitters | Not phased (device or behavioral study) | Completed | Dec 22, 2020 | Dec 1, 2025 (actual) |
| NCT03889899 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. | Not phased (device or behavioral study) | Recruiting | Oct 21, 2020 | 2026-06 (estimated) |
| NCT04002479 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer | Not phased (device or behavioral study) | Active, not recruiting | Oct 20, 2020 | 2026-10 (estimated) |
| NCT04543903 | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer | Not phased (device or behavioral study) | Completed | May 16, 2022 | Oct 1, 2025 (actual) |
| NCT06202118 | A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients. | Not phased (device or behavioral study) | Recruiting | Feb 19, 2024 | 2026-01 (estimated) |
| NCT05065346 | Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | 2025-03 | 2025-12 (estimated) |
| NCT06202339 | Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT). | Not phased (device or behavioral study) | Not yet recruiting | 2024-04 | 2026-04 (estimated) |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases | Not phased (device or behavioral study) | Terminated | Aug 28, 2019 | Nov 30, 2023 (actual) |
| NCT05125354 | A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT | Not listed | Completed | Jan 6, 2022 | Mar 6, 2022 (actual) |
| NCT04377360 | Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors | Not phased (device or behavioral study) | Completed | Jan 6, 2020 | Mar 28, 2022 (actual) |
| NCT03353077 | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) | Not phased (device or behavioral study) | Completed | Nov 21, 2017 | Jul 14, 2019 (actual) |
| NCT03015883 | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma | Not phased (device or behavioral study) | Completed | Feb 22, 2017 | Jun 1, 2019 (actual) |